Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.

By L. Farilla, A. Bulotta, B. Hirshberg, S. Li Calzi, Nasif Khoury, Houtan Noushmehr, C. Bertolotto, U. di Mario, D. Harlan, R. Perfetti. Endocrinology, 2003

691 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/0c1413264b76c8fd04f45047735931adc7e7f77f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Josephine M. Egan
2. Wook Kim
3. Ralph DeFronzo
4. Jens J. Holst
5. I. Tabas
6. K. Bornfeldt

In Genetics

1. Ralph DeFronzo
2. Stephen R. Bloom

In Surgery

1. Josephine M. Egan
2. Wook Kim
3. Ralph DeFronzo
4. Jens J. Holst

Citations in the corpus

• The physiology of glucagon-like peptide 1. (2007, background): “Most recently, GLP-1 has been shown to be capable of inhibiting apoptosis of beta cells including human beta cells (30, 65).”
• Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters (2006, background): “GLP-1 is produced from the same entero-endocrine cells (L cells) as PYY and acts as an incretin, releasing insulin(21) and improving pancreatic -cell function in rodents.(22) Reduction in food intake has also been reported.”
• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus (2009, background): “In vivo studies in rodents (296,297) and in vitro studies with cultured human islets (298) have shown that exenatide can expand -cell mass and prevent apoptosis of islets, respectively.”
• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “Moreover, cAMP/PKA-dependent activation of CREB can mediate antiapoptotic effects of GLP-1 in cells through up-regulation of Bcl-2 and Bcl-xL expression (Farilla et al., 2003; Hui et al., 2003; Ranta et al., 2006).”